; carboplatin 800 mg/m 2 modulated by tamoxifen 120 mg/m 2 /day × 5 days) with a median interval of 3.2 months. CR rate was 20% after induction chemotherapy and 33% and 54% after HDC cycles I and II, respectively. Sixteen patients (55%) failed to complete HDC cycle II within 200 days because of disease progression, toxicity, inadequate stem cell collection, insurance denials or patient choice. Median progression-free survival (PFS) for all 29 patients entered is 301 days from date of HDC cycle I and actuarial PFS at 2 years is 35%. For the 13 patients who received the two cycles of HDC-ASCS, actuarial PFS at 2 years was 54% (P = NS compared to those receiving only one cycle). These data show that a second cycle of full-dose intensity HDC-ASCS may increase the proportion of patients with MBC that achieve CR and may increase PFS. However, a large proportion of patients that complete HDC-ASCS cycle I may fail to proceed to cycle II in a timely fashion. Bone Marrow Transplantation (2000) 25, 519-524. Keywords: breast cancer; high-dose chemotherapy; stem cell transplantation Despite early detection methods and the availability of an increasing number of active chemotherapy agents, breast
cancer was responsible for the deaths of 44 000 women in the United States in 1997. 1 Patients with metastatic disease and hormone receptor negative tumors have a median response duration to chemotherapy of less than 1 year, and long-term survival is unusual. 2, 3 High-dose chemotherapy facilitated by autologous hematopoietic stem cell support (HDC-ASCS) has been studied in several series without randomized controls [4] [5] [6] [7] [8] [9] [10] and two reported randomized studies 11, 12 as a means of improving results obtained by conventional-dose chemotherapy in this group of patients. These studies have demonstrated high complete response rates (35-55%), but progression-free survival (PFS) at 3-5 years has been only 15-25%. Better results (3-year PFS 30-40%) have been obtained in patients who receive HDC-ASCS while in complete response. 10 Dose-intensification beyond levels achieved in reported studies of single-cycle HDC-ASCS may be of further benefit. However, such intensification is limited by non-hematologic toxicity and can only be safely achieved using more than one cycle of HDC-ASCS. Additionally, the Gompertzian kinetics predicted for breast cancer by the NortonSimon hypothesis 13 imply that repeated cycles of HDC-ASCS are more likely to be effective than a single cycle. Furthermore, two cycles of high-dose chemotherapy have been reported to improve results in the therapy of metastatic neuroblastoma. 14 The feasibility of administering two cycles of high-dose chemotherapy, each with hematopoietic cell support, in metastatic breast cancer has been demonstrated by a number of authors. 7, 11, 15, 16 Most studies have employed either two identical cycles of a multi-agent high-dose chemotherapy regimen 7, 11 or a multi-agent cycle in combination with a cycle of high-dose melphalan. 15, 16 The majority of these studies could not clearly demonstrate improved results compared to what could be expected with a single cycle of high-dose therapy. However, Bitran et al 16 reported a better outcome than that usually achieved in trials of single-cycle HDC. No randomized studies of single vs multiple cycles of HDC-ASCS have been reported. Thus, the question of whether tandem HDC-ASCS is more effective than a single cycle remains unresolved. Furthermore, a proportion of patients who undergo a single cycle of high-dose chemotherapy may be unable to proceed to the second cycle because of disease progression, adverse effects or refusal from insurance carriers. If this proportion is sizeable, it may limit the applicability of such an approach in practice.
Here, we report the results of a phase II study of two non-identical, unattenuated cycles of multi-agent HDC-ASCS for women with chemotherapy-responsive metastatic breast cancer, who fulfilled standard eligibility criteria for single-cycle HDC-ASCS at our institution. The objectives of this study were to estimate the proportion of patients who could successfully proceed to the second cycle, the toxicity of this approach in a population not specifically selected for ability to withstand double cycle HDC-ASCS, and to determine whether such an approach will produce an improved progression-free survival than the 15-25% typically observed with single cycles of high-dose therapy.
Patients and methods

Eligibility criteria
Criteria used were identical to those for single cycle highdose chemotherapy at our institution: histologically documented breast cancer and measurable/evaluable metastatic lesions (р3 organs involved) prior to induction chemotherapy; female patients aged between 18 and 65 years; satisfactory organ function (bilirubin and AST р2 × normal; creatinine clearance у60 ml/min; left ventricular ejection fraction (LVEF) у45%; FEV1 and DLCO у50% of predicted; WBC у3/nl, platelets у100/nl). WHO performance status р2 and life expectancy Ͼ3 months were required. CNS involvement, HIV positivity, pregnancy, serious active infections and previous anthracycline dosage equivalent to Ͼ450 mg/m 2 of doxorubicin were exclusion criteria. The study was approved by the Human Subjects Committee of the University of California, San Diego. All patients gave written informed consent.
All patients received induction chemotherapy prior to administration of HDC-ASCS. The regimen used was left to the discretion of the referring physician. Attainment of CR or PR in response to induction therapy was required before proceeding to HDC-ASCS. /day s.c.). When stem cells were mobilized using chemotherapy, leukaphereses were initiated when the WBC reached у2/nl and the platelet count reached 50/nl after the nadir. When PBSC were mobilized using growth factors, leukaphereses were initiated on day 5. Target collection was Ͼ4 × 10 In all patients completing two cycles of HDC, half of the total collection was infused with each cycle.
Mobilization and collection of hematopoietic cells
High-dose chemotherapy
The general scheme of the two consecutive HDC regimens employed is indicated in Figure 1 . Inpatient stay was required for both regimens. The drugs in HDC cycle I were administered in equally divided doses over 4 consecutive days (day −5 to −2). MESNA was administered by continuous infusion over 4 days starting with the first dose of cyclophosphamide. All patients were hydrated starting 12 h prior to the first dose of cyclophosphamide. Urine output was maintained at Ͼ3 ml/kg/h and urine specific gravity was maintained at Ͻ1.01 with the administration of diuretics if necessary. PBSC +/− BM were re-infused on day 0.
Patients were eligible for HDC cycle II after cycle I if the following conditions were met: there had been no progression of disease; stable recovery of hematopoietic function (ANC Ͼ1.5/nl and platelet count Ͼ100/nl) was present and no grade 4 non-hematologic toxicity had occurred. Patients were also required subjectively to feel recovered from aesthenia and other toxicities attributable to HDC I and insurance approval for the second cycle was required. HDC cycle II was administered within 200 days of HDC cycle I. Etoposide, thiotepa and carboplatin were administered in equally divided doses over 4 consecutive days (day −5 to −2). Tamoxifen was administered at 40 mg p.o. three times daily for 5 days (day −5 to −1). The use of tamoxifen in this context was based upon previous reported studies from our institution describing synergism between high doses of tamoxifen and platinum chemotherapy. [17] [18] [19] Prophylactic heparin (5000 units s.c. three times daily day −5 to 0 ) was used to minimize the risk of thromboembolic complications. PBSC +/− BM were re-infused on day 0 as for HDC cycle I.
Following both regimens, GM-CSF (250 g/m 2 /day s.c.) was administered from day +1 until the ANC was higher than 3/nl for 3 consecutive days. Prophylactic antimicrobials (ciprofloxacin 500 mg p.o. twice daily, fluconazole 100 mg p.o. twice daily and acyclovir 800 mg p.o. twice daily) were used from the first day of the high-dose chemotherapy regimen until neutrophil recovery. Analgesics and empiric anti-microbial therapy were used as required.
Therapy and follow-up after high-dose chemotherapy
Patients with estrogen receptor positive disease were commenced on tamoxifen (20 mg/day) after achieving hematopoietic recovery from HDC cycle II or when it was determined that the patient would not undergo HDC cycle II. Treatment was continued for a planned 5 years or until there was evidence of disease progression. Patients with one or two areas of residual disease after completing HDC, which could be encompassed within a radiation port were treated with consolidative radiation therapy at the discretion of the referring physician. Evaluation of extent of systemic disease was performed prior to administration of HDC cycle II, at least every 6 months for the first 24 months after completion of high-dose therapy, and yearly thereafter.
Definition of response
Measurable lesions were assessed by physical examination or radiological imaging before administration of HDC cycle I, after completion of cycle I and after completion of cycle II. Complete response (CR) was defined as disappearance of all evidence of tumor for at least 4 weeks. In addition, patients who had complete disappearance of all measurable/evaluable disease and had normalization of tumor markers but had persistence of abnormalities on bone scan or skeletal X-rays without evidence of progression over 4 weeks were classified as having achieved a CR. Partial response (PR) was defined as 50% or greater decrease of the product sum of all bi-dimensionally measured lesions for 4 weeks. Disease progression was defined as Ͼ25% increase in the product sum or appearance of new lesions.
Statistical analysis
Overall survival (OS) and progression-free survival (PFS) were calculated from the first day of high-dose chemotherapy until death or the time when progressive disease was first documented, respectively. Actuarial OS and PFS survival curves were estimated using the Kaplan-Meier product limit method. Survival curves were compared using Bone Marrow Transplantation the log-rank test. Medians and frequencies are used for descriptive statistics.
Results
Patient characteristics
Twenty-nine patients were enrolled on to the study. Their characteristics are summarized in Table 1 . Visceral (hepatic or pulmonary) involvement with metastatic disease was present in 14 patients. Five patients had soft-tissue involvement only and six patients had metastatic disease restricted to bone. All patients were treated with standard dose chemotherapy prior to HDC with one (n = 17) or more than one regimens (n = 12).
Thirteen patients completed both cycles of high-dose chemotherapy and are fully evaluable. Sixteen patients were unable to proceed to HDC cycle II for reasons listed below. Three patients were denied a second cycle by their insurance company. Four patients could not proceed to cycle II because of toxicity encountered during cycle I (LVEF fell to Ͻ45%, one patient; slow hematopoietic recovery, two patients; fatal sepsis, one patient). Six patients had evidence of disease progression before cycle II could be administered. One patient did not yield sufficient stem cells (Ͼ2 × 10 6 CD34 + cells/kg) for the second cycle. This patient received both peripheral blood stem cells and bone marrow after HDC cycle I. Two patients elected to not proceed with cycle II because they determined that family and occupational commitments, respectively, were incompatible with the admission required for the procedure. All criteria listed in the Methods section above had to be fulfilled before HDC II was administered. Thus, median time between HDC cycles I and II was 3.2 months (range 1.7-6.1 months). The 15 patients whose tumors were estrogen receptor positive were treated with tamoxifen after completing their final cycle of HDC (nine patients after HDC cycle I, six patients after HDC cycle II). Three patients received consolidative radiation following their final cycle of HDC (two patients had completed one HDC cycle and one patient had completed HDC cycle II).
Toxicity
Only one patient died from a non-relapse cause (Aspergillus vasculitus with occlusive thrombus of basilar artery on day 14 following HDC cycle I). No other patient encountered greater than grade 3 non-hematologic toxicity after either cycle of HDC. Grade 3 toxicities following HDC cycle I were: nausea (2), vomiting (2), diarrhea (3), hematuria (1), mucositis (4), infections (2, Streptococcus viridans septicemia, Hickmann catheter sepsis with Staphylococcus epidermidis), hypertension (1), hypotension (1). Grade 3 toxicities following HDC cycle II were: diarrhea (4), mucositis (4), infections (1, Hickmann catheter sepsis with Micrococcus), hyponatremia (1).
Engraftment
Median times to reach ANC Ͼ1/nl and platelets Ͼ20/nl were 17 days (range 13-36) and 18 days (range 16-52 (85) 12 (75) Hormone receptor = estrogen receptor or progesterone receptor; NA = data not available; CR = complete response; PR = partial response.
days), respectively, for patients undergoing HDC cycle I. For HDC cycle II, median times to achieve ANC Ͼ1/nl and platelets Ͼ20/nl were 15 days (14-20 days) and 18 days (15-25 days), respectively.
Response
Six patients (20%) were in a CR and 23 were in PR following induction (standard-dose) chemotherapy (Table 1) . Twenty-seven patients were evaluable on first reassessment (1-2 months) following HDC cycle I. Nine patients (33%) achieved CR, 14 were in PR (51%), four patients showed evidence of progression (15%). Thirteen patients proceeded to HDC cycle II. Four were in CR, eight were in PR and one patient was not evaluable for response. The response achieved upon first reassessment (1-2 months) following HDC cycle II was CR in seven patients (54%) and PR in six patients (46%). Thus, three patients were converted from PR to CR after administration of HDC cycle II. Of the five patients remaining in PR after HDC cycle II and evaluable for a comparative assessment of response between cycles I and II, three achieved a further disease response after HDC cycle II (defined as a 25% reduction of evaluable/measurable parameters over HDC cycle I).
Survival and progression-free-survival
Actuarial PFS and OS for all 29 patients entered on study is shown in Figures 2a and 3a , respectively. Median PFS is 301 days and actuarial PFS at 2 years is 35%. The median overall survival is 619 days and actuarial overall survival (OS) at 2 years is 48%. Four patients remain alive and free of disease at 741, 917, 1320 and 1770 days following the first cycle of HDC. Another five patients are alive with evidence of recurrence at a median of 1238 days following HDC cycle I. For the 13 patients who received the two cycles of HDC (Figures 2b and 3b) , actuarial PFS at 2 years was 54% and OS at 2 years was 68%. However, the differences in actuarial PFS or OS survival seen in patients undergoing one or two cycles of HDC were not statistically significant (log-rank test).
Discussion
Although it has been postulated that in advanced breast cancer more than one cycle of HDC-ASCS may be necessary to eradicate disease 16, 20 conflicting results have been reported by phase II studies. Dunphy et al 7 and Ayash et al 21 showed no advantage in long-term disease-free survival of patients treated with two cycles of HDC-ASCS when compared to historical controls receiving a single cycle of HDC-ASCS. However, the study by Dunphy et al has been criticized for inadequate dose-intensity and the results of Ayash et al may have been affected by sequencing of high-dose melphalan with respect to the other cycle of HDC. 16, 22 Bitran et al 16 reported a freedom from treatment failure of 56% at 24 months with acceptable toxicity for patients treated on their tandem regimen. Furthermore, in patients achieving a CR after two cycles of HDC-ASCS, freedom from treatment failure was 88% at 24 months. As most studies of HDC-ASCS have demonstrated a high early relapse rate, these results suggest an improved outcome for patients receiving tandem HDC-ASCS. Bezwoda et al 11 reported a statistically significant advantage in OS and PFS for patients treated with their double-transplant regimen when compared to patients treated with conventional-dose chemotherapy. However, it is of note that the long-term disease-free survival of transplanted patients was similar to that seen with studies using single cycles of HDC-ASCS. In our study, some patients that had achieved only a PR after HDC cycle I achieved a CR after HDC cycle II, and additional reductions in tumor burden were noted in some of the remaining patients. Patients undergoing two cycles of HDC on our study had a higher PFS and OS than patients completing only one cycle. While encouraging, and consistent with the findings of Bitran et al, 16 the differences were not statistically significant and may have resulted from selection of more physically fit patients, and of patients with less aggressive disease by the criteria required to proceed to cycle II. Randomized studies will be required for a more definitive comparison between single and multi-cycle HDC regimens.
As studies using more than one cycle of HDC-ASCS may be perceived as more onerous than studies using a single cycle, investigators may select younger and more physically fit patients for such studies. This may generate a confounding bias when the results of multiple cycle HDC-ASCS are compared to that of historical controls using a single cycle. Furthermore, collection of a higher number of stem cells than required for a single cycle of HDC-ASCS is usually a pre-requisite for entry on to tandem protocols producing a further selection bias.
Our study was designed to include all patients who would be candidates for a single cycle of HDC-ASCS. An objective of this study was to determine what proportion of patients entered could not proceed to HDC-ASCS cycle II because of patient tolerability, progression of disease, lack of sufficient stem cells or insurance denials. The results of this study demonstrate that full-intensity tandem HDC cannot be achieved in a substantial proportion of patients who are eligible for a single cycle of HDC-ASCS. Although the proportion of patients not proceeding to cycle II because of insurance denials and personal reasons may vary, it is of note that 10 patients (34%) could not proceed to HDC cycle II because of toxicity or disease progression. Thus, irrespective of the efficacy of this approach, it is of limited applicability as a means of improving long-term outcome in patients with metastatic breast cancer. Bitran et al 16 reported a similar incidence of failure to proceed to cycle II of HDC due to toxicity or disease progression (33%). Ayash et al 15, 21 reported that all patients completing HDC cycle I proceeded to cycle II on their study. However, HDC cycle I on their trial consisted of melphalan alone (140-180 mg/m 2 ) and no formal reassessment of disease status was performed between cycles I and II. A lower incidence of failure to complete all cycles has also been seen in trials of tandem autologous transplants as initial therapy in metastatic breast cancer 11, 22 and may relate to increased tolerance of HDC in patients who have not been subjected to induction chemotherapy.
Because of the use of a regular HDC regimen for cycle I in our study and an emphasis on patient safety, the time interval between the two cycles was flexible (1.7 to 6 months) to ensure adequate recovery from cycle I prior to the initiation of cycle II. An alternative approach recently used by a number of investigators involves the adminis-tration of multiple cycles of less than maximal high-dose chemotherapy, each with progenitor cell support administered at short intervals. [23] [24] [25] [26] Such a strategy does not require full recovery of platelet counts or aesthenia prior to progression to subsequent cycles of therapy, and may minimize the number of patients that fail to complete the planned treatment because of disease progression or toxicity. This approach has also been advocated on a theoretical basis for maximal efficacy. 20 However, no study with such an approach has yet demonstrated superior long-term outcomes for patients with metastatic disease.
In summary, in a significant proportion of patients with metastatic breast cancer who had undergone a single-cycle of high dose chemotherapy, a second cycle of maximal HDC-ASCS could not be administered because of toxicity or disease progression. Other patients failed to proceed to HDC-ASCS cycle II because of insurance denials, inability to collect adequate stem cells and individual preference. Alternative approaches to multiple-cycle HDC-ASCS are needed in these patients. Strategies designed to enhance the efficacy of a single cycle of HDC-ASCS, eg immunotherapeutic approaches, biological response modifiers or lowdose maintenance chemotherapy following one HCD-ASCS cycle are currently being tested in this role.
